Cimerli Interchangeable Biosimilar Approved Without Switching Data
Coherus Ranibizumab Rival Will Compete With Lucentis And Byooviz In US
Executive Summary
Citing low risk of a clinically impactful immunogenic response from systemic anti-drug antibodies and intraocular inflammation when alternating between Coherus’ Cimerli and Genentech’s reference product ranibizumab, US FDA says a switching study would not be informative.
You may also be interested in...
From Interchangeability To Invisibility: FDA Wipes Designation From Biosimilar Labels
Amid continuing stakeholder confusion over the meaning and significance of the US FDA’s interchangeability designation for biosimilars, the agency has now recommended omitting altogether details of interchangeability from biosimilar labels.
From Interchangeability To Invisibility: FDA Wipes Designation From Biosimilar Labels
Amid continuing stakeholder confusion over the meaning and significance of the US FDA’s interchangeability designation for biosimilars, the agency has now recommended omitting altogether details of interchangeability from biosimilar labels.
Stelara Biosimilars In Wings, Will Proposed Red Tape Elimination Act Aid Biosimilars Push?
As Stelara biosimilars wait in the wings, proposed legislation in the US could ease the path to commercialization. The Draft Red Tape Elimination Act aims to remove a requirement for switching studies. Opposition to the bill is expected, but if passed how much will the Act move the biosimilars needle in the country?